Stevens-johnson syndrome/Toxic epidermal necrolysis (TEN)
- May 2022
- 10min
Therapeutic classes inducing this adverse event
Antiangiogenic agent, BRAF inhibitor, CTLA4 inhibitor, Chemotherapy, Cyclin-dependent kinase 4/6 inhibitor, EGFR inhibitor, Hormone therapy, KIT inhibitor, MEK inhibitor, PD-1 inhibitor, RAF inhibitor, Radiotherapy, SMO inhibitor, mTOR inhibitor
- 1/2
- 2/2
CTCAE V5.0
Skin sloughing covering <10% BSA with associated signs(e.g.,erythema, purpura, epidermal detachment and mucous membrane detachment)
SIMPLIFIED GRADING
Skin sloughing covering <10% BSA (stevens-johnson syndrome)
References
Peuvrel L, Cassecuel J, Bernier C, Quéreux G, Saint-Jean M, Le Moigne M, Frénard C, Khammari A, Dréno B; Supported by GESTIM Nantes group of cutaneous adverse events induced by cancer treatments. TOXICAN: a guide for grading dermatological adverse events of cancer treatments. Support Care Cancer. 2018;26:2871-7.
CTCAE V5.0
Skin sloughing covering >=10% BSA with associated signs (e.g., erythema, purpura, epidermal detachment and mucous membrane detachment)
SIMPLIFIED GRADING
Skin sloughing of 10% to 30% of BSA (SJS/TEN) or more than 30% of BSA (TEN)
References
Peuvrel L, Cassecuel J, Bernier C, Quéreux G, Saint-Jean M, Le Moigne M, Frénard C, Khammari A, Dréno B; Supported by GESTIM Nantes group of cutaneous adverse events induced by cancer treatments. TOXICAN: a guide for grading dermatological adverse events of cancer treatments. Support Care Cancer. 2018;26:2871-7.
Browse for more adverse events